The Global State of Pernicious Anaemia Awareness

Why where you live still shapes how well you’re diagnosed and treated

Pernicious Anaemia (PA) is not a rare condition, but awareness of it remains deeply uneven across the world. In 2026, a person’s experience of diagnosis and treatment can still depend heavily on geography, healthcare systems, and even cultural dietary patterns.
What emerges is not just a medical issue, but a global patchwork of understanding. Some patients receive timely, effective care, while others face years of misdiagnosis, under-treatment, or dismissal.

A Tale of Two Challenges: Western vs Emerging Contexts

In North America and Europe, the problem is rarely a lack of resources. Instead, it is often a reliance on outdated laboratory reference ranges and rigid diagnostic frameworks.

In countries like the United States and Canada, patients may technically have access to advanced testing such as methylmalonic acid (MMA). However, this access is often shaped by insurance coverage. The result is a diagnosis gap, where those who cannot afford additional testing may remain undiagnosed or undertreated.

Across Europe, and particularly in the United Kingdom, the picture is different but equally complex. National healthcare systems provide broad access to treatment, yet standard protocols can be restrictive. Many patients receive hydroxocobalamin injections at fixed intervals, often every two to three months, regardless of ongoing symptoms.

While this ensures baseline care, it can leave patients feeling that treatment is not tailored to their individual needs.

Beyond these systems, an additional diagnostic challenge exists that cuts across multiple regions. Many healthcare systems remain heavily focused on iron deficiency anaemia, often overlooking vitamin B12 deficiency entirely. In diets rich in folate, such as those common in parts of East Asia, anaemia can be partially corrected while neurological damage caused by B12 deficiency continues silently.

At the same time, simultaneous iron and B12 deficiencies are common. This can produce normocytic blood cells rather than the macrocytic cells typically associated with PA, making standard screening less reliable and increasing the risk of missed diagnosis.

India and the Global South: A Different Diagnostic Challenge

In countries such as India, the issue is often not access to testing, but interpretation.

Vitamin B12 deficiency is widespread, largely due to dietary patterns, particularly in populations with high rates of vegetarianism. However, this creates a diagnostic blind spot. Pernicious anaemia, the autoimmune form of B12 deficiency, is frequently mistaken for a simple nutritional deficiency.

These two causes require very different approaches. A dietary deficiency can often be managed with supplements. Pernicious Anaemia requires lifelong treatment, most often with injections. When this difference is missed, patients may be given short-term or inadequate treatment, allowing symptoms to persist or worsen over time.

At the same time, gastrointestinal infections and malabsorption conditions further complicate diagnosis, making it even harder to identify the underlying cause of deficiency.

This pattern is also seen in parts of Latin America and the Middle East, where clinical attention is often directed toward iron deficiency and broader nutritional concerns. While vitamin B12 deficiency itself is widely recognised, the autoimmune nature of Pernicious Anaemia is frequently under-identified due to limited diagnostic tools and a lack of region-specific research.

In Latin America, for example, a significant proportion of the population shows clinical or subclinical B12 deficiency, with estimates suggesting around 40% of children and adults are affected (Hunt et al., 2014). However, Pernicious Anaemia is often not distinguished from dietary causes. In some cases, severe B12 deficiency has even been mistaken for more acute conditions such as thrombotic thrombocytopenic purpura due to overlapping laboratory findings (Yousaf et al., 2017).

There are, however, encouraging developments. Research in the region is increasingly focused on maternal and child health, exploring how nutrient deficiencies interact with inflammation during pregnancy (González-Fernández et al., 2024), which may improve early detection and understanding over time.

In the Middle East, awareness is growing but remains inconsistent. Population studies suggest that B12 deficiency may be more prevalent than folate deficiency in some countries. In Iran, for example, a population-based study found that nearly 26% of healthy adults had low B12 levels (WHO EMRO, 2018), yet identifying the underlying cause is still a challenge. In resource-limited or conflict-affected settings, clinical priorities often centre on iron deficiency, which accounts for a large proportion of anaemia cases. Advanced diagnostic testing, such as intrinsic factor antibody assays, is often unavailable.

Research in the region tends to focus on specific groups, such as young women or students. For instance, a study in Makkah, Saudi Arabia, identified young females as a significant risk group for B12 deficiency (Basalamah et al., 2023), with limited long-term data on autoimmune conditions like Pernicious Anaemia. This contributes to an ongoing gap between prevalence and accurate diagnosis.

A Global “Lottery” of Treatment Protocols

One of the most striking features of PA care worldwide is the lack of consistency. Treatment approaches vary significantly depending on where a patient lives:

• UK / Europe: Hydroxocobalamin injections, typically every 2–3 months, with growing advocacy for more frequent dosing
• USA / Canada: Cyanocobalamin injections (often monthly) or high-dose oral supplements, with access shaped by cost and insurance
• Australia: Similar protocols to the UK, but with increasing focus on GP education and policy reform
• India: Predominantly oral supplementation, with a gradual shift toward recognising the need for injections in autoimmune cases

In East Asia, including China, Japan, and South Korea, the landscape is evolving. Pernicious Anaemia is increasingly recognised not as rare, but as under-diagnosed. Diets rich in fish and fermented foods may provide enough B12 to mask early deficiency, delaying diagnosis of autoimmune causes.

Research in China has demonstrated that clinical presentation closely mirrors Western cases, with growing interest in the role of Helicobacter pylori infection as a contributing factor to gastric atrophy and malabsorption.

Japan, with a long history of haematological research, has developed a more standardised diagnostic approach. There is strong clinical awareness of subclinical deficiency, particularly in older populations, where B12 deficiency may mimic or worsen cognitive decline. Advanced antibody testing is more routinely used, allowing for more definitive diagnosis.

In South Korea, recent studies have challenged the assumption that PA is rare, showing that it accounts for a substantial proportion of B12 deficiency cases, with one study reporting approximately 24%. Patients often present with complex features, including pancytopenia and coexisting autoimmune conditions, highlighting the need for continued clinical education.

In Russia, Pernicious Anaemia has historically been recognised under different terminology, with strong emphasis on identifying megaloblastic anaemia through blood and bone marrow analysis. Modern practice is increasingly incorporating antibody testing and endoscopic evaluation to confirm autoimmune causes. However, as in many countries, milder cases can still be overlooked at the primary care level. Research is now focusing on autoimmune gastritis, cancer risk, and the impact of B12 deficiency in aging populations.

This variation creates what many patients describe as a “lottery”, where the quality and frequency of treatment can depend more on location than on clinical need.

The Rise of the Patient Expert

In recent years, one of the most significant shifts has not come from healthcare systems, but from patients themselves.

Online communities, including global Facebook groups and forums, have created a new kind of knowledge exchange. A patient in Melbourne can now access the same research, experiences, and treatment discussions as someone in London or New York.
This has led to the emergence of the “patient expert”, individuals who are deeply informed about their condition and increasingly confident in advocating for their care.

It has also exposed inconsistencies. What is considered a “normal” B12 level in one country may be viewed as insufficient in another. Japan, for instance, maintains higher thresholds than many Western nations, raising important questions about what constitutes true deficiency.

Inequality, Economics, and the Cost of Being Missed

Pernicious Anaemia does not only affect individuals. It carries a wider societal cost.

The condition often develops during peak working years, typically between the 30’s and 50’s. When diagnosis is delayed, symptoms such as fatigue, cognitive impairment, and neurological changes can significantly impact productivity.

Globally, this translates into lost working hours, increased healthcare use, and long-term disability, particularly when neurological damage is not addressed early.

There is also a clear economic case for earlier diagnosis. Improving awareness and screening could reduce long-term healthcare costs, especially those linked to neurological care, falls, and chronic complications.

Where Do We Go From Here?

Despite these challenges, there are signs of progress.

In the UK, recent updates from National Institute for Health and Care Excellence (NICE) have begun to shift the conversation, placing greater emphasis on symptom-based treatment rather than strict reliance on blood test thresholds. These guidelines are increasingly being referenced by patient advocates in countries such as Australia and New Zealand, who are calling for similar changes.

For meaningful global improvement, several shifts are needed:

• Greater awareness among healthcare professionals that anaemia is often a late-stage symptom, not a requirement for diagnosis
• Better alignment of B12 reference ranges across countries
• A stronger focus on patient-reported symptoms alongside laboratory results
• Updated medical education on the autoimmune nature of Pernicious Anaemia

There is also a clear need to expand research beyond traditionally studied regions, ensuring that autoimmune causes of B12 deficiency are better understood in Latin America, the Middle East, Africa, and parts of Asia where current data remains limited.

A Shared Goal

The global state of Pernicious Anaemia awareness is improving, but not evenly.

Progress will depend on closing the gap between countries, systems, and approaches. Whether in the UK, India, or elsewhere, the goal remains the same: earlier recognition, more personalised treatment, and a focus on preventing long-term harm.

As a charity dedicated to improving the diagnosis and treatment of Pernicious Anaemia worldwide, the Pernicious Anaemia Society plays a key role in driving this progress. Through raising awareness, supporting patients, and encouraging research, the aim is to ensure that no one is overlooked because of where they live.